

Korea DPR Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Korea DPR					
2. Grant number: 1820-PRK-04a-X / 12-PRK-08a-Y					
3. Date of Decision Letter: 14 December 2017					
4. Date of the Partnership Framework Agreement: 7 June 2013					
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine					
6. Vaccine type: Pentavalent					
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID					
8. Programme duration¹: 2012 -2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)					
	2012-2017	2018	2019	2020	Total ²
Programme Budget (US\$)	12,514,838 ³	1,069,500	1,049,000	1,049,000	15,682,338
10. Vaccine introduction grant (in US\$): A VIG of US\$61,000 was disbursed on 3 April 2012 and US\$39,000 on 4 October 2012, with return of the unused balance of US\$ 203 on 20 August 2014.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴					
Type of supplies to be purchased with Gavi funds in each year	2012-2017	2018			
Number of Pentavalent vaccines doses		922,100			
Annual Amounts (US\$)	12,514,838 ⁵	1,069,500			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1820-PRK-04a-X-C</p> <p>According to the co-financing policy, DPR Korea falls within the initial self-financing group.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>									
Type of supplies to be purchased with Country funds in each year	2018	2019	2020						
Number of vaccine doses	192,300	199,800	199,800						
Value of vaccine doses (US\$)	207,587								
Total co-financing payments (US\$) (including freight)	223,000	226,000	226,000						
<p>15. Operational support for campaigns: Not applicable</p>									
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2018</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>				Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
<p>17. Financial clarifications: Not applicable.</p>									
<p>18. Other conditions: Not applicable.</p>									

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 14 December 2017